BUSINESS● LOWSep 24 · Sep 24, 2026, 5:17 PM
Ligand, AvenCell ink financing deal worth up to $47M for CAR-T therapies
Seeking Alpha Tech · global
Ligand and AvenCell have finalized a financing agreement valued at up to $47 million for the development of CAR-T therapies. This deal supports research and development in the biotechnology and pharmaceutical sectors.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS28m agoNigeria-Indonesia investment to boost GDP, create jobs, says NICCI president, BalogunVanguard NigeriaBUSINESS33m agoTelangana to unveil new Aerospace and Defence Policy 2.0 soon, says RevanthThe Hindu